CARY, N.C., Oct. 20, 2021 -- Two North Carolina companies, analytics leader SAS and venture investment firm Pappas Capital, are joining forces to help advance the state as a global...
TargeGen successfully completed enrollment of a multi-center clinical trial of TG101348
SAN DIEGO, May 14, 2009 /PRNewswire/ -- TargeGen, Inc. today announced that the Company successfully completed enrollment of a multi-center clinical trial of TG101348, an oral, potent, and highly selective inhibitor of JAK2 in patients with myelofibrosis on May 7, 2009.
